Suppliers and packagers for generic pharmaceutical drug: nedosiran sodium

nedosiran sodium

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842	NDA	Novo Nordisk	0169-5306-10	1 SYRINGE in 1 CARTON (0169-5306-10) / 1 mL in 1 SYRINGE	2024-02-19
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842	NDA	Novo Nordisk	0169-5307-08	1 SYRINGE in 1 CARTON (0169-5307-08) / .8 mL in 1 SYRINGE	2024-02-19
Novo	RIVFLOZA	nedosiran sodium	SOLUTION;INJECTION	215842	NDA	Novo Nordisk	0169-5308-01	1 VIAL in 1 CARTON (0169-5308-01) / .5 mL in 1 VIAL	2024-02-19

Suppliers for Nedosiran Sodium: Manufacturing, Contract Supply, and Source-of-API Map

Last updated: May 26, 2026

Nedosiran sodium supply is concentrated among specialized oligonucleotide and cGMP sterile/intermediate manufacturers. Upstream API and conjugate-grade oligonucleotide intermediates are typically sourced through contract development and manufacturing organizations (CDMOs) rather than broad commodity nucleotide suppliers, because nedosiran sodium production requires controlled synthesis, purification, oligo characterization, and end-to-end regulatory documentation.

Core supply reality: nedosiran sodium is not a widely diversified “off-the-shelf” active ingredient with a large public supplier panel. Procurement and sourcing are usually tied to the drug’s clinical and commercial manufacturing package, including defined starting materials, validated analytical methods, and lot release systems.

---

Which companies supply nedosiran sodium API and drug product?

Featured snippet: Supply is handled through the originator’s manufacturing network and CDMOs, with the most traceable suppliers being those listed as manufacturing parties on regulatory submissions and labeling, and those appearing in patent and CMC documentation for the oligonucleotide process.

What to look for in public records

The most defensible “supplier” identifiers for nedosiran sodium are:

• Manufacturer/labeler on FDA approval or product label (for drug product)
• API or intermediate manufacturing sites referenced in CMC sections and inspection records
• Patent assignees and their process partners (often recurring CDMO names across process families)
• Distributor and “market authorization holder” structure by territory (commercial supply differs from API supply)

Supply-chain segmentation

• API synthesis and purification: oligonucleotide manufacturing (controlled synthesis, deprotection, purification, characterization)
• Conjugate/particle-forming steps (if applicable to the design): linker chemistry and final assembly
• Drug product manufacturing: fill-finish, sterile filtration, container closure system, labeling and packaging
• Quality systems: oligo integrity assays (charge, sequence confirmation), residual solvents/reagents, endotoxin, sterility assurance

---

Who are the most likely nedosiran sodium CDMOs (oligonucleotide and fill-finish)?

Featured snippet: The likely supplier set is limited to CDMOs with proven capacity for oligonucleotide active ingredient manufacture and sterile injectable fill-finish under cGMP.

Common CDMO capabilities required for nedosiran sodium

• Oligonucleotide synthesis under cGMP (including scale-up from clinical to commercial lots)
• Robust oligo QC: identity, purity, integrity, and impurity profiling
• Sterile injectable fill-finish capability (aseptic processing or terminal sterilization depending on formulation constraints)
• Stability-indicating method sets for shelf-life release

Market behavior for this modality

For rare-disease oligonucleotide therapies, commercial supply is often maintained by:

• a primary commercial drug substance site and
• a single or small set of sterile fill-finish sites to preserve manufacturing consistency

---

What does the FDA regulatory package show about nedosiran sodium manufacturing sites?

Featured snippet: FDA product labeling and approval-era CMC disclosures are the best public anchors for identifying manufacturing sites tied to nedosiran sodium.

Where manufacturing information appears

• Drug label: “Manufactured for” and “Manufactured by” statements
• Summary basis for approval (SBD) and CMC sections (where accessible)
• Inspection and quality system references through FDA databases

---

What patents identify nedosiran sodium manufacturing partners?

Featured snippet: Process patents typically tie the oligonucleotide synthesis steps and purification approaches to assignees and sometimes to named process collaborators.

Patent estate mapping logic

For sourcing decisions, the patent estate is used to:

• confirm the critical process steps (where supply fragmentation risks arise)
• identify assignees that usually run manufacturing oversight
• locate process-specific implementations that CDMOs must replicate under license or tech transfer

---

How many companies can supply nedosiran sodium without requalification risk?

Featured snippet: The number is typically small for oligonucleotide drugs because tech transfer, validated methods, and comparability packages narrow eligible suppliers.

Requalification and comparability barriers

A new CDMO or API site generally requires:

• process and analytical method transfer
• alignment on impurity profile and control strategy
• stability studies and comparability bridging for commercial readiness

---

Which generic or biosimilar pathways affect nedosiran sodium supply options?

Featured snippet: Competitive sourcing pressure is limited until an approved non-licensed alternative exists; otherwise, supply remains locked to the originator’s manufacturing network.

Why it matters

If the market lacks approved alternatives, procurement tends to track:

• originator supply contracts
• licensed manufacture
• contract roles supporting the originator rather than third-party generic sourcing

---

What sourcing options exist for nedosiran sodium procurement (API vs finished dose)?

Featured snippet: Buyers typically choose between:

• direct purchase of finished drug product through the branded supply chain
• licensed or contract procurement of API/DS intermediates only where partnerships and regulatory access exist

Decision drivers

• regulatory responsibility for release
• lot traceability needs
• lead times for oligonucleotide synthesis and fill-finish
• quality agreements covering characterization and deviations

---

Key Takeaways

• Nedosiran sodium supply is dominated by a small set of specialized oligonucleotide manufacturers and sterile fill-finish partners rather than broad pharmaceutical raw material distributors.
• The most reliable public supplier identifiers come from FDA-related labeling/manufacturing statements and CMC-linked manufacturing site disclosures.
• New entrants face execution barriers tied to tech transfer, validated analytical methods, impurity control, and comparability packaging.
• For procurement, the practical split is finished drug product through the branded supply chain versus licensed/contract API sourcing only where regulatory and IP access exists.

---

FAQs

1. How do I identify the actual manufacturer for nedosiran sodium finished drug product?
   Use the labeling “Manufactured by/for” text and cross-check with FDA approval-era manufacturing site disclosures.

2. Can a standard nucleotide CDMO supply nedosiran sodium without a tech transfer package?
   Typically not, because oligonucleotide therapeutics require validated process controls and stability-indicating QC methods.

3. What is the biggest supply bottleneck for nedosiran sodium manufacturing?
   Oligonucleotide synthesis and purification under validated cGMP controls, plus sterile fill-finish readiness.

4. What procurement route is safer: finished dosage or API sourcing?
   Finished dosage generally avoids downstream comparability and release responsibility complexity.

5. Do patents limit who can manufacture nedosiran sodium?
   The patent estate can constrain process work, purification strategies, and key chemical steps, which affects whether CDMOs can act without licensing and tech transfer.

---

References

1. FDA. “Drug Labels” (access via Drugs@FDA).
2. FDA. “Drugs@FDA” database.
3. FDA. “Summary Basis of Approval” (where available for the relevant application).
4. USPTO / Espacenet. Nedosiran sodium patent families and assignee/process disclosures.